An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters.

The FDA on Tuesday approved the Lilly (NYSE: LLY) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each one lasting between 15 minutes and two hours. The cause of cluster headaches is not known, and they have no cure. The current standard of treatment includes triptans, an older class of drugs that treat migraine pain after it starts.

Galcanezumab is part of a… Read more »